CareDx, Inc (NASDAQ:CDNA) Shares Acquired by ClariVest Asset Management LLC

ClariVest Asset Management LLC grew its stake in CareDx, Inc (NASDAQ:CDNA) by 2.9% during the second quarter, Holdings Channel.com reports. The fund owned 64,027 shares of the company’s stock after acquiring an additional 1,810 shares during the period. ClariVest Asset Management LLC’s holdings in CareDx were worth $994,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. GAMMA Investing LLC raised its position in CareDx by 1,021.8% in the second quarter. GAMMA Investing LLC now owns 2,210 shares of the company’s stock valued at $34,000 after purchasing an additional 2,013 shares during the period. Quest Partners LLC acquired a new stake in shares of CareDx in the fourth quarter valued at $117,000. Allspring Global Investments Holdings LLC raised its holdings in shares of CareDx by 10,267.2% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 18,661 shares of the company’s stock valued at $198,000 after buying an additional 18,481 shares during the period. Janney Montgomery Scott LLC purchased a new stake in shares of CareDx in the 1st quarter valued at $238,000. Finally, Price T Rowe Associates Inc. MD lifted its stake in CareDx by 8.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 29,396 shares of the company’s stock worth $312,000 after acquiring an additional 2,344 shares in the last quarter.

Insider Activity at CareDx

In other CareDx news, insider Alexander L. Johnson sold 21,557 shares of the firm’s stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $32.58, for a total transaction of $702,327.06. Following the transaction, the insider now owns 284,983 shares of the company’s stock, valued at $9,284,746.14. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other CareDx news, insider Alexander L. Johnson sold 21,557 shares of CareDx stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $32.58, for a total value of $702,327.06. Following the transaction, the insider now directly owns 284,983 shares in the company, valued at $9,284,746.14. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Alexander L. Johnson sold 34,231 shares of the stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $33.55, for a total transaction of $1,148,450.05. Following the sale, the insider now owns 284,983 shares of the company’s stock, valued at approximately $9,561,179.65. The disclosure for this sale can be found here. Insiders sold a total of 91,340 shares of company stock valued at $3,025,415 over the last ninety days. Insiders own 4.20% of the company’s stock.

CareDx Trading Down 0.0 %

CareDx stock opened at $28.53 on Thursday. CareDx, Inc has a 12-month low of $4.80 and a 12-month high of $34.84. The stock has a market cap of $1.50 billion, a P/E ratio of -8.34 and a beta of 1.76. The company has a fifty day simple moving average of $23.92 and a 200-day simple moving average of $16.06.

CareDx (NASDAQ:CDNA) last announced its quarterly earnings results on Wednesday, July 31st. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.37. The firm had revenue of $92.27 million during the quarter, compared to the consensus estimate of $67.20 million. CareDx had a negative return on equity of 53.65% and a negative net margin of 53.73%. As a group, sell-side analysts forecast that CareDx, Inc will post -0.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have issued reports on CDNA. BTIG Research upgraded shares of CareDx from a “neutral” rating to a “buy” rating and set a $40.00 price target on the stock in a research note on Monday, August 19th. Craig Hallum upped their target price on shares of CareDx from $22.00 to $32.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. Wells Fargo & Company initiated coverage on shares of CareDx in a research report on Tuesday, August 27th. They issued an “underweight” rating and a $28.00 price target for the company. HC Wainwright reaffirmed a “neutral” rating on shares of CareDx in a research report on Thursday, August 1st. Finally, The Goldman Sachs Group increased their price objective on CareDx from $16.00 to $26.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, CareDx has a consensus rating of “Moderate Buy” and an average target price of $28.80.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.